Intensive ldl cholesterol targeting
Intensive ldl cholesterol targeting has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Mar 28, 2026: “Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease”.
1 paper studies it1 findingUpdated
See all 1 papers on intensive ldl cholesterol targeting
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“A primary end-point event occurred in 100 patients (Kaplan-Meier estimate of cumulative incidence, 6.6%) in the intensive-targeting group and in 147 patients (Kaplan-Meier estimate of cumulative incidence, 9.7%) in the conventional-targeting group (hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.86; P = 0.002).”
- 1 lab in 1 country
- Funders: Cardiovascular Research Center and 1 more
- Human trial1
Studies in people
1 study gave intensive ldl cholesterol targeting to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of cardiovascular eventsHR 0.67, 95% CI 0.52–0.86, 6.6% vs 9.7% | Randomized trial3 years | 3,048 peopleSecondary prevention in patients with atherosclerotic cardiovascular disease | The New England journal of medicine, Mar 28, 2026 |
What is intensive ldl cholesterol targeting linked with?
1Studies link intensive ldl cholesterol targeting with 1 measure, most often cardiovascular events (1 study).
Cardiovascular events
downin humans1HR 0.67
1 study
Cardiovascular events
downin humans1HR 0.67
Intensive ldl cholesterol targeting lowers the risk of cardiovascular events in humans (secondary prevention in patients with atherosclerotic cardiovascular disease) (HR 0.67, 95% CI 0.52–0.86, 6.6% vs 9.7%).
“A primary end-point event occurred in 100 patients (Kaplan-Meier estimate of cumulative incidence, 6.6%) in the intensive-targeting group and in 147 patients (Kaplan-Meier estimate of cumulative incidence, 9.7%) in the conventional-targeting group (hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.86; P = 0.002).”
Human trialsecondary prevention in patients with atherosclerotic cardiovascular disease3 yearsn = 3,048
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
The New England journal of medicine